Ulrich Finckh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ulrich Finckh has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Arndt Rolfs
2 shared publicationsH Rommelspacher
2 shared publicationsHans Rommelspacher
2 shared publicationsHelmut Harms
2 shared publications- Lutz G. Schmidt
Department of Psychiatry, Johannes Gutenberg-University Mainz, Untere Zahlbacher Str. 8, 55131 Mainz, Germany
2 shared publications Peter Dufeu
2 shared publications
Latest Publications
- 7 September 2004
- Published by Georg Thieme Verlag KG in Aktuelle Neurologie
- Vol. 31 (S 1) , P566
Charcot-Marie-Tooth-Erkrankung mit disseminierter Encephalomyelopathie - Kreuzreaktion einer Immunreaktion gegen defektes Myelin?
Bei der Charcot-Marie-Tooth-Erkrankung (CMT) kommt es aufgrund von Mutationen in Genen verschiedener Myelinproteine zu einem defekthaften Aufbau des peripheren Myelins und auch zu axonaler Degeneration. Eventuell durch die Myelininstabilität und daraus folgende chronische Resorptionsvorgänge kann offenbar unabhängig davon, welches Gen die Mutation trägt, eine Immunreaktion gegen peripheres Myelin getriggert werden. Diese kann sich klinisch als sekundäre entzündliche Neuropathie mit schubförmigen Verschlechterung der Nervenfunktion präsentieren. Wir berichten von vier Fällen mit einer hereditären Neuropathie mit assoziierter disseminierter Encephalomyelopathie. Hierbei handelt es sich um einen Patienten mit einer CMT1a aufgrund einer PMP22-Duplikation, einen Patienten mit einer CMT1b auf dem Boden einer Mutation im Myelinprotein 0-Gen und eine Patientin mit einer CMTx bei Mutation im Connexin-32 kodierenden Gen. Bei der vierten Patientin liegt eine hereditäre gemischt axonale-demyelinisierende Neuropathie mit zentraler Beteiligung ohne bisher bekannte Mutation vor. Der Patient mit der CMT1b, die Patientin mit CMTx und die mit der bisher unbekannten Mutation zeigten im MRT im zerebralen Marklager multiple, disseminierte Signalveränderungen, die denen einer multiplen Sklerose ähneln, während der Patient mit der CMT1a nach einem Unfall, der mit multiplen Nervenquetschungen einherging, eine ausgedehnte flächige Leukencephalopathie entwickelte. Drei der vier Patienten entwickelten kognitive Einschränkungen. Schubförmige neurologische Ausfälle in Form von Optikusneuritiden, Hirnstammsyndromen und einer Hemiparese traten bei den beiden weiblichen Patienten auf. Bei dem Patienten mit der CMT1b wurde wiederholt eine erhöhte Zellzahl im Liquor und bei der Patientin mit der bisher nicht bekannten Mutation eine intrathekale Immunglobulin-Synthese festgestellt. Bei dem Patienten mit der CMT1b und dem Patientin mit der CMTx ist auch die Neuropathie im Vergleich zu betroffenen Verwandten deutliche stärker ausgeprägt. Die beschrieben vier Fälle legen nahe, dass es bei der CMT unabhängig von der Art der Mutation nicht nur zu einer sekundären entzündlichen Neuropathie, sondern auch zu einer Kreuzimmunreaktion gegen das zentrale Myelin kommen kann. Das klinische Spektrum ist hierbei breit. Die Krankheit kann ähnlich wie eine multiple Sklerose verlaufen.
- 7 September 2004
- Published by Georg Thieme Verlag KG in Aktuelle Neurologie
- Vol. 31 (S 1) , P566
Charcot-Marie-Tooth-Erkrankung mit disseminierter Encephalomyelopathie - Kreuzreaktion einer Immunreaktion gegen defektes Myelin?
Bei der Charcot-Marie-Tooth-Erkrankung (CMT) kommt es aufgrund von Mutationen in Genen verschiedener Myelinproteine zu einem defekthaften Aufbau des peripheren Myelins und auch zu axonaler Degeneration. Eventuell durch die Myelininstabilität und daraus folgende chronische Resorptionsvorgänge kann offenbar unabhängig davon, welches Gen die Mutation trägt, eine Immunreaktion gegen peripheres Myelin getriggert werden. Diese kann sich klinisch als sekundäre entzündliche Neuropathie mit schubförmigen Verschlechterung der Nervenfunktion präsentieren. Wir berichten von vier Fällen mit einer hereditären Neuropathie mit assoziierter disseminierter Encephalomyelopathie. Hierbei handelt es sich um einen Patienten mit einer CMT1a aufgrund einer PMP22-Duplikation, einen Patienten mit einer CMT1b auf dem Boden einer Mutation im Myelinprotein 0-Gen und eine Patientin mit einer CMTx bei Mutation im Connexin-32 kodierenden Gen. Bei der vierten Patientin liegt eine hereditäre gemischt axonale-demyelinisierende Neuropathie mit zentraler Beteiligung ohne bisher bekannte Mutation vor. Der Patient mit der CMT1b, die Patientin mit CMTx und die mit der bisher unbekannten Mutation zeigten im MRT im zerebralen Marklager multiple, disseminierte Signalveränderungen, die denen einer multiplen Sklerose ähneln, während der Patient mit der CMT1a nach einem Unfall, der mit multiplen Nervenquetschungen einherging, eine ausgedehnte flächige Leukencephalopathie entwickelte. Drei der vier Patienten entwickelten kognitive Einschränkungen. Schubförmige neurologische Ausfälle in Form von Optikusneuritiden, Hirnstammsyndromen und einer Hemiparese traten bei den beiden weiblichen Patienten auf. Bei dem Patienten mit der CMT1b wurde wiederholt eine erhöhte Zellzahl im Liquor und bei der Patientin mit der bisher nicht bekannten Mutation eine intrathekale Immunglobulin-Synthese festgestellt. Bei dem Patienten mit der CMT1b und dem Patientin mit der CMTx ist auch die Neuropathie im Vergleich zu betroffenen Verwandten deutliche stärker ausgeprägt. Die beschrieben vier Fälle legen nahe, dass es bei der CMT unabhängig von der Art der Mutation nicht nur zu einer sekundären entzündlichen Neuropathie, sondern auch zu einer Kreuzimmunreaktion gegen das zentrale Myelin kommen kann. Das klinische Spektrum ist hierbei breit. Die Krankheit kann ähnlich wie eine multiple Sklerose verlaufen.
- 1 August 2004
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 28 (Supplement) , 37A
SH-SY5Y CELLS ARE A MODEL TO STUDY DOPAMINE D2 RECEPTOR (DRD2) AND TRANSPORTER (DAT) ADAPTATION DURING ETHANOL AND DRUG EXPOSURE.
- 1 August 2004
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 28 (Supplement) , 37A
SH-SY5Y CELLS ARE A MODEL TO STUDY DOPAMINE D2 RECEPTOR (DRD2) AND TRANSPORTER (DAT) ADAPTATION DURING ETHANOL AND DRUG EXPOSURE.
- 1 April 1999
- Vol. 23 (4) , 578-81
Lack of an allelic association between polymorphisms of the dopamine D2 receptor gene and alcohol dependence in the German population.
Our study examined recent claims of an association of the TaqI A1 allele and the functional -141C Ins allele of the dopamine D2 receptor (DRD2) gene with alcohol dependence. Genotypes of the TaqI A and -141C insertion/deletion polymorphisms were assessed in 196 German nonalcoholic controls and 310 German alcohol-dependent subjects, including two more homogeneous subgroups selected by either a history of parental alcoholism (n = 108) or by a history of severe physiological alcohol withdrawal symptoms (n = 99). We found no association between any of the biallelic variants or the A1/Ins haplotype and alcohol dependence (p > 0.05). Our present association results failed to replicate evidence that either the TaqI A1 allele or the functional Ins allele or the A1/Ins haplotype of the DRD2 gene confers vulnerability to alcohol dependence in the German population.
- 1 April 1999
- Vol. 23 (4) , 578-81
Lack of an allelic association between polymorphisms of the dopamine D2 receptor gene and alcohol dependence in the German population.
Our study examined recent claims of an association of the TaqI A1 allele and the functional -141C Ins allele of the dopamine D2 receptor (DRD2) gene with alcohol dependence. Genotypes of the TaqI A and -141C insertion/deletion polymorphisms were assessed in 196 German nonalcoholic controls and 310 German alcohol-dependent subjects, including two more homogeneous subgroups selected by either a history of parental alcoholism (n = 108) or by a history of severe physiological alcohol withdrawal symptoms (n = 99). We found no association between any of the biallelic variants or the A1/Ins haplotype and alcohol dependence (p > 0.05). Our present association results failed to replicate evidence that either the TaqI A1 allele or the functional Ins allele or the A1/Ins haplotype of the DRD2 gene confers vulnerability to alcohol dependence in the German population.
- 1 August 1997
- Published by Wolters Kluwer Health in Pharmacogenetics
- Vol. 7 (4) , 271-281
Influence of the dopamine D2 receptor (DRD2) genotype on neuroadaptive effects of alcohol and the clinical outcome of alcoholism
The present study was performed to test the hypotheses that allelic variants at the human dopamine D2 receptor gene locus (DRD2) confer susceptibility to alcoholism or are associated with clinical subtypes of alcoholism. We investigated anA^G substitution polymorphism in the 3'-untranslated region of exon 8 (E8) of DRD2 with allele frequencies of/G=0.295 - 0.329. No significant association of the DRD2 genotype or allele frequencies with alcoholism was found in an association study including 283 alcoholics and 146 non-alcoholic controls. However, the frequent homozygous E8 A/A genotype with fAA=0.47 - 0.48 was associated with increased anxiety and depression scores in alcoholics during the follow up after clinical detoxification treatment. In addition, E8 A/A was associated with increased suicide attempts and showed a tendency towards more severe withdrawal symptoms, early relapse and reduced responsiveness to the dopaminergic agonist apomorphine. Regression analysis revealed the DRD2 E8 genotype as the only significant factor determining withdrawal severity in female alcoholics. The findings suggest an influence of the DRD2 genotype on the neuropharmacological effects of chronic alcohol exposure and the clinical course of alcoholism.
- 1 August 1997
- Published by Wolters Kluwer Health in Pharmacogenetics
- Vol. 7 (4) , 271-281
Influence of the dopamine D2 receptor (DRD2) genotype on neuroadaptive effects of alcohol and the clinical outcome of alcoholism
The present study was performed to test the hypotheses that allelic variants at the human dopamine D2 receptor gene locus (DRD2) confer susceptibility to alcoholism or are associated with clinical subtypes of alcoholism. We investigated anA^G substitution polymorphism in the 3'-untranslated region of exon 8 (E8) of DRD2 with allele frequencies of/G=0.295 - 0.329. No significant association of the DRD2 genotype or allele frequencies with alcoholism was found in an association study including 283 alcoholics and 146 non-alcoholic controls. However, the frequent homozygous E8 A/A genotype with fAA=0.47 - 0.48 was associated with increased anxiety and depression scores in alcoholics during the follow up after clinical detoxification treatment. In addition, E8 A/A was associated with increased suicide attempts and showed a tendency towards more severe withdrawal symptoms, early relapse and reduced responsiveness to the dopaminergic agonist apomorphine. Regression analysis revealed the DRD2 E8 genotype as the only significant factor determining withdrawal severity in female alcoholics. The findings suggest an influence of the DRD2 genotype on the neuropharmacological effects of chronic alcohol exposure and the clinical course of alcoholism.
- 1 May 1996
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 20 (3) , 528-532
No Association of the Structural Dopamine D2 Receptor (DRD2) Variant 311Cys with Alcoholism
The human dopamine D2 receptor (DRD2) has been implied in the vulnerability for alcoholism and/or the modification of its severity. This is supported through animal experimental and pharmacological data. We analyzed the DRD2 311Ser/Cys polymorphism in 312 German alcoholics and 131 ethnically matched controls to investigate the association of genetic DRD2 variants with alcoholism or clinical characteristics of homogeneous subgroups of alcoholics. We observed no association between the 311Cys variant and alcoholism, and none of the clinical characteristics evaluated was significantly associated with 311Cys. The allele frequencies of the 311Cys variant were 0.026 and 0.031 in the alcoholics and controls, respectively. These are the highest reported 311Cys frequencies in Caucasians. The DRD2 TaqI A1/A2 restriction fragment length polymorphism was analyzed simultaneously in our samples. In most cases, the 311Cys allele is associated with the TaqI A2-allele. Data do not suggest a clinical relevance of the 311Cys variant in alcoholism. However, the relevance of this variant in other diseases or the existence of other DRD2 variants with altered receptor function or expression cannot be excluded.
- 1 May 1996
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 20 (3) , 528-532
No Association of the Structural Dopamine D2 Receptor (DRD2) Variant 311Cys with Alcoholism
The human dopamine D2 receptor (DRD2) has been implied in the vulnerability for alcoholism and/or the modification of its severity. This is supported through animal experimental and pharmacological data. We analyzed the DRD2 311Ser/Cys polymorphism in 312 German alcoholics and 131 ethnically matched controls to investigate the association of genetic DRD2 variants with alcoholism or clinical characteristics of homogeneous subgroups of alcoholics. We observed no association between the 311Cys variant and alcoholism, and none of the clinical characteristics evaluated was significantly associated with 311Cys. The allele frequencies of the 311Cys variant were 0.026 and 0.031 in the alcoholics and controls, respectively. These are the highest reported 311Cys frequencies in Caucasians. The DRD2 TaqI A1/A2 restriction fragment length polymorphism was analyzed simultaneously in our samples. In most cases, the 311Cys allele is associated with the TaqI A2-allele. Data do not suggest a clinical relevance of the 311Cys variant in alcoholism. However, the relevance of this variant in other diseases or the existence of other DRD2 variants with altered receptor function or expression cannot be excluded.
- 1 January 1996
- Vol. 21 (1) , 38-42
Absence of human T-lymphotrophic virus type I in patients with systemic lupus erythematosus.
The role of the human T-cell lymphotropic/leukaemia virus type I (HTLV-I) in the pathogenesis of autoimmune diseases of unknown cause, such as systemic lupus erythematosus (SLE), multiple sclerosis (MS) or Sjögren's syndrome (SS) has been discussed extensively. We have investigated whether SLE is in any way associated with exogenous HTLV-I. Using enzyme immunoassay (EIA), we found no seroreactivity against HTLV-I antigens in any of 24 SLE patients under investigation. Using a radioimmunoprecipitation assay (RIPA), there was also no expression of retroviral tax-protein demonstrable in 24 individuals with SLE. DNA preparations of peripheral blood cells, as well as isolated CD4- and CD8-positive cells, were examined for HTLV-I sequences (pol-, env-, gag-, LTR- and tax-region) using polymerase chain reaction (PCR). We were unable to demonstrate any specific HTLV-I PCR products in SLE specimens. Our data suggest that exogenous HTLV-I is not involved in the pathogenesis of SLE. Systemic lupus erythematosus (SLE) is a multisystem disease of unknown cause characterized by B-cell hyperactivity with hypergammaglobulinaemia and the formation of pathogenic autoantibodies. Patients may also show altered suppressor/helper T-cell ratios. Abnormalities in T-cell function include T-cell lymphopenia, expression of activation antigens and alteration of responses to mitogens and lymphokines. Human retroviruses are known to cause immune aberrations, such as diminished T-cell function and polyclonal B-cell stimulation, which are observed in patients with leukaemias, lymphomas and the acquired immunodeficiency syndrome (AIDS). Human T-cell lymphotropic/leukaemia (HTLV-I) is aetiologically linked with adult virus type I T-cell leukaemia (ATL) and tropical spastic paraparesis. A common feature of the HTLV family is an LTR encoded protein (tax protein, p40tax) which triggers viral protein production in the early stages of a retroviral infection. Detection of p40tax may indicate transcriptional activity of a provirus. Several investigators have examined the possible involvement of HTLV-I in SLE and have produced conflicting results, especially so far as seroreactivity against HTLV-I antigens is concerned. The discovery of HTLV-I like particles in murine lupus might also indicate an important role of exogenous viruses in SLE. Olsen and colleagues describe a high seropositivity to anti-HTLV-I- and anti-HTLV-III antibodies and evidence of viral replication in patients with SLE. Lin et al. also demonstrated anti-HTLV-I antibodies in SLE patients. However, other authors failed to detect anti-HTLV-I antibodies, proviral structures or viral transcripts in SLE. We investigated whether or not there are any indications of the presence of the exogenous retrovirus, HTLV-I, in patients with SLE, at immunological and genetic levels. We found neither immunological nor molecular biological evidence for the existence of HTLV-I in SLE patients. There were some weak suggestions of the presence of possibly endogenous retroviral sequences.
- 1 January 1996
- Vol. 21 (1) , 38-42
Absence of human T-lymphotrophic virus type I in patients with systemic lupus erythematosus.
The role of the human T-cell lymphotropic/leukaemia virus type I (HTLV-I) in the pathogenesis of autoimmune diseases of unknown cause, such as systemic lupus erythematosus (SLE), multiple sclerosis (MS) or Sjögren's syndrome (SS) has been discussed extensively. We have investigated whether SLE is in any way associated with exogenous HTLV-I. Using enzyme immunoassay (EIA), we found no seroreactivity against HTLV-I antigens in any of 24 SLE patients under investigation. Using a radioimmunoprecipitation assay (RIPA), there was also no expression of retroviral tax-protein demonstrable in 24 individuals with SLE. DNA preparations of peripheral blood cells, as well as isolated CD4- and CD8-positive cells, were examined for HTLV-I sequences (pol-, env-, gag-, LTR- and tax-region) using polymerase chain reaction (PCR). We were unable to demonstrate any specific HTLV-I PCR products in SLE specimens. Our data suggest that exogenous HTLV-I is not involved in the pathogenesis of SLE. Systemic lupus erythematosus (SLE) is a multisystem disease of unknown cause characterized by B-cell hyperactivity with hypergammaglobulinaemia and the formation of pathogenic autoantibodies. Patients may also show altered suppressor/helper T-cell ratios. Abnormalities in T-cell function include T-cell lymphopenia, expression of activation antigens and alteration of responses to mitogens and lymphokines. Human retroviruses are known to cause immune aberrations, such as diminished T-cell function and polyclonal B-cell stimulation, which are observed in patients with leukaemias, lymphomas and the acquired immunodeficiency syndrome (AIDS). Human T-cell lymphotropic/leukaemia (HTLV-I) is aetiologically linked with adult virus type I T-cell leukaemia (ATL) and tropical spastic paraparesis. A common feature of the HTLV family is an LTR encoded protein (tax protein, p40tax) which triggers viral protein production in the early stages of a retroviral infection. Detection of p40tax may indicate transcriptional activity of a provirus. Several investigators have examined the possible involvement of HTLV-I in SLE and have produced conflicting results, especially so far as seroreactivity against HTLV-I antigens is concerned. The discovery of HTLV-I like particles in murine lupus might also indicate an important role of exogenous viruses in SLE. Olsen and colleagues describe a high seropositivity to anti-HTLV-I- and anti-HTLV-III antibodies and evidence of viral replication in patients with SLE. Lin et al. also demonstrated anti-HTLV-I antibodies in SLE patients. However, other authors failed to detect anti-HTLV-I antibodies, proviral structures or viral transcripts in SLE. We investigated whether or not there are any indications of the presence of the exogenous retrovirus, HTLV-I, in patients with SLE, at immunological and genetic levels. We found neither immunological nor molecular biological evidence for the existence of HTLV-I in SLE patients. There were some weak suggestions of the presence of possibly endogenous retroviral sequences.
- 1 January 1996
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 21 (1) , 38-42
Absence of human T-lymphotrophic virus type I in patients with systemic lupus erythematosus
- 1 January 1996
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 21 (1) , 38-42
Absence of human T-lymphotrophic virus type I in patients with systemic lupus erythematosus